Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583102 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
A Phase 1 study, sponsored by University of Iowa.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00583102 is a Phase 1 study that was terminated before completion, run by University of Iowa. The registered enrollment target is 23 participants.
The verdict
NCT00583102, a Phase 1 study, was terminated before completion, sponsored by University of Iowa.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of combining a drug known as Lovastatin to the chemotherapy drug cytarabine. Lovastatin is currently used to lower blood cholesterol levels and lab data suggests that it increases the anti-leukemia activity of cytarabine. This research is being done because high doses of cytarabine induce remissions in only about 25% of patients with acute myeloid leukemia.
Interventions
- DRUG Cytarabine
- DRUG Lovastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2001-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583102
The ClinicalTrials.gov registry entry for NCT00583102 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT00583102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583102 about?
NCT00583102 is a clinical study titled "Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML". The purpose of this study is to test the safety and effectiveness of combining a drug known as Lovastatin to the chemotherapy drug cytarabine. Lovastatin is currently used to lower blood cholesterol levels and lab data suggests that it increases the anti-leukemia activity of cytarabine. This researc...
What is the current status of trial NCT00583102?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2001-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00583102?
The interventions under investigation include: Cytarabine (DRUG), Lovastatin (DRUG).
Who is sponsoring clinical trial NCT00583102?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.